As for Shkreli's claim that the profits will fund future research and development for a new drug, Emanuel doesn't buy it.
"The reason is nothing more than this guy saw a hole in the market he could exploit," he said. "He’s a hedge fund guy, he's not a researcher. We don’t need another drug in this space, so it’s just garbage and he knows it." Cases where companies buy up generic drugs and jack up the prices with no additional research, though, are increasingly common, he added.
While Emanuel notes that Daraprim is used by only about 10,000 to 12,000 people per year, that doesn't make the price hike any less egregious.
"In this particular case, people will adapt and hospitals will adapt," Emanuel said. "But there is a limit that the system can take in terms of drug pricing."